EICHOR
● Active Not Recruiting
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Condition: Platinum Sensitive · BRCA Mutated · Relapsed Ovarian Cancer · Sponsor: AstraZeneca
About this study
A Phase III, randomised, double-blind, placebo-controlled, multi-centre study to assess the efficacy of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary peritoneal and / or fallopian tube cancer) or high grade endometrioid cancer with BRCA mutations (documented mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious (known or predicted to be detrimental/lead to loss of function)) who have responded following platinum based chemotherapy.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (126)
| University of Alabama at Birmingham | Birmingham, Alabama, United States | — |
| Palo Alto Foundation Medical Group | San Francisco, California, United States | — |
| University of Colorado | Aurora, Colorado, United States | — |
| The Hospital of Central Connecticut | New Britain, Connecticut, United States | — |
| Gynecologic Cancer Center | Orlando, Florida, United States | — |
| North Shore University | Evanston, Illinois, United States | — |
| Greater Baltimore Medical Center | Baltimore, Maryland, United States | — |
| Johns Hopkins | Baltimore, Maryland, United States | — |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | — |
| Massachusetts General Hospital | Boston, Massachusetts, United States | — |
| MD Anderson at Cooper Cancer Center | Voorhees Township, New Jersey, United States | — |
| Womens Cancer Care Associates | Albany, New York, United States | — |
+ 114 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.